Key result
The proposed ban on hydroxyethyl starch solutions is highly debated, with experts disagreeing on the interpretation of existing trial data and the European Medicines Agency's regulatory decisions.
Answers are grounded in this paper and cite their sources.
The authors argue against the proposed ban on hydroxyethyl starch (HES), highlighting methodological flaws in the trials used to justify the ban and criticizing the EMA's rushed recommendation.
Roberts and colleagues'1Roberts I Shakur H Bellomo R et al.Hydroxyethyl starch solutions and patient harm.Lancet. 2018; 391: 736Summary Full Text Full Text PDF PubMed Scopus (33) Google Scholar Correspondence in The Lancet asking WHO to support a ban on the use of hydroxyethyl starch (HES) deserves clarification. First, registration of HES is not yet suspended; a legally binding decision by the European Commission is still pending. Second, Roberts and colleagues claim that HES was used to treat postpartum haemorrhage in the WOMAN trial.2WOMAN Trial CollaboratorsEffect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.Lancet. 2017; 389: 2105-2116Summary Full Text Full Text PDF PubMed Scopus (737) Google Scholar In fact, the publication doesn't provide any information about HES treatment or its related adverse events. Third, the authors refer to their own studies as examples of high-quality trials, but these have been publicly criticised for methodological deficiencies and severe limitations.3Marx G Schindler AW Mosch C et al.Intravascular volume therapy in adults: guidelines from the Association of the Scientific Medical Societies in Germany.Eur J Anaesthesiol. 2016; 33: 488-521Crossref PubMed Scopus (76) Google Scholar Notably, several inconsistencies have prompted medical societies and journals to ask for open access of CHEST data,4Doshi P Data too important to share: do those who control the data control the message?.BMJ. 2016; 352: i1027Crossref PubMed Scopus (25) Google Scholar, 5DGAIOpen Letter to the European Commission.https://www.dgai.de/aktuelles/464-offener-brief-im-namen-von-19-europaeischen-anaesthesiegesellschaften-an-die-europaeische-kommission-zur-ueberpruefung-der-zulassung-des-volumenersatzmittels-hydroxyethylstaerke-hes.htmlDate: March 16, 2018Date accessed: May 26, 2018Google Scholar unfortunately without success. The so-called independent reanalysis of this study was published by the original authors themselves.6Doshi P “Independent” reanalysis of landmark starch solutions trial was published by original authors.BMJ. 2017; 358: j3552Crossref PubMed Scopus (4) Google Scholar 19 European national anaesthesiological societies expressed their surprise and disagreement when the European Medicines Agency (EMA) rushed the far-reaching recommendation to suspend the registration of HES on such a questionable basis. The EMA ignored increasing evidence indicating that starches seem to positively affect patient outcomes, and actively decided against waiting for the results of two large randomised controlled trials (initiated by EMA themselves) investigating the safety and efficacy of HES in the context of surgery and trauma (NCT03338218 and NCT03278548). Speculation from Roberts and colleagues that manufacturers of HES might be putting vulnerable patients in low-income countries at risk in the future distracts from the real major global health issue: clinical decisions in Europe are no longer based on data and scientific debate but on majority decisions made by authorities. DC has received lecture honoraria and research grants from B Braun, Fresenius Kabi, and Grifols. MJ has received lecture honoraria and research grants from Baxter, B Braun, CSL Behring, Fresenius Kabi, Grifols, and Serumwerke. MJ is a member of the albumin advisory board of Grifols. Hydroxyethyl starch solutions and patient harmTo the Director General of WHO, Full-Text PDF Should hydroxyethyl starch be banned?Two recent letters in The Lancet regarding the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation to suspend the marketing of hydroxyethyl starch (HES) could hardly be more different, yet both raise highly pertinent points. Djillali Annane and colleagues1 emphasise that the PRAC decision was far from unanimous, and that the European Medicines Agency's own selected panel of experts advised PRAC against this decision. The authors further emphasised the problems that can arise in resuscitation in cases “when crystalloids alone are not sufficient”. Full-Text PDF EMA recommendation to suspend HES is hazardousIn 2013, the European Medicines Agency (EMA) restricted the use of solutions containing hydroxyethyl-starch (HES) in critically ill patients with sepsis, burns, and impaired kidney function while maintaining authorisation for the treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient.1 On Jan 12, 2018, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended the suspension of HES from the European market.2 On Jan 26, the EMA's Coordination Group for Mutual Recognition and Decentralised Procedures—Human (CMDh) approved this recommendation by 15 to 13. Full-Text PDF Should hydroxyethyl starch be banned? – Authors' replyMedicines should be licensed for use when there is reliable evidence that patients benefit from them. In their Correspondences, Michael Frank James and colleagues and Hans-Joachim Priebe overlook this crucial point. Instead, they cast doubt on the high-quality randomised trials that question the safety of hydroxyethyl starch (HES), or claim that future studies might show some benefit for its use. They wrongly assert that CHEST trial data are being withheld when these are probably the only fluid trial data that have been independently reanalysed (confirming the integrity of the analysis and conclusions), and which remain available for further analysis in accordance with the sponsor's open data policy. Full-Text PDF Should hydroxyethyl starch be banned?In their Correspondence in The Lancet, Ian Roberts and colleagues (Feb 12, p 736)1 ask the director general of WHO to ban the use of hydroxyethyl starch (HES) solutions worldwide “to protect patients”. Several clarifications and corrections are needed to place the authors' arguments into proper perspective.
No takes yet. Share an insight, caveat, or question.
Chappell et al. (2018) conducted a letter in Hypovolaemia. Hydroxyethyl starch (HES) was evaluated. The proposed ban on hydroxyethyl starch solutions is highly debated, with experts disagreeing on the interpretation of existing trial data and the European Medicines Agency's regulatory decisions.
Synapse has enriched 10 related papers. Consider them for comparative context: